Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med

March 9, 2023
The Central Social Insurance Medical Council (Chuikyo) on March 8 approved a batch of medicines for their reimbursement listing on March 15, with Eli Lilly’s diabetes drug Mounjaro (tirzepatide) boasting the biggest peak sales projection among them, at over 30...read more